CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

Core Viewpoint - CASI Pharmaceuticals, Inc. is advancing its CID-103 clinical program, targeting organ transplant rejection and autoimmune diseases, with a focus on renal allograft antibody mediated rejection (AMR) [1] Financial Results - The company reported its business and financial results for the third quarter ended September 30, 2025 [1] Clinical Development - CID-103 is positioned as a potential best-in-class anti-CD38 monoclonal antibody [1] - The clinical program for CID-103 is first being conducted in the U.S. under an already approved IND, followed by a regulatory package that has been accepted and is under review in China [1]